drugset
drugset / Trial / NCT05240404

Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma

NCT05240404 ↗

Phase 2 Unknown 116 enrolled Xiangya Hospital of Central South University
RandomizedParallel-groupOpen-labelTreatment

Summary

This phase II study is to evaluate the efficacy of the adjuvant immunotherapy after curative-intent ablation for recurrent hepatocarcinoma

Timeline

Start
2020-07-01
Primary completion
2023-07-31
Completion
2024-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Toripalimab Monoclonal antibody 240 mg Intravenous

Indications

hepatocellular carcinoma